Anthrax Research Today is a free monthly online journal that collates and summarizes the latest research about Anthrax, including details on bacillus anthracis, contagiousness, exposure, effects.

Volume 2 (2006), Issue 12 (December)

1. The HC fragment of tetanus toxin forms stable, concentration-dependent dimers via an intermolecular disulphide bond.
   J Mol Biol, 365(1): 123-34. [Abstract] [Full-text]
2. Cloning and expression in E. coli of a functional Fab fragment obtained from single human lymphocyte against anthrax toxin.
   Mol Immunol, 44(8): 2101-6. [Abstract] [Full-text]
3. Destruction of spores on building decontamination residue in a commercial autoclave.
   Appl Environ Microbiol, 72(12): 7687-93. [Abstract] [Full-text]
4. Anthrax pathogen evades the mammalian immune system through stealth siderophore production.
   Proc Natl Acad Sci U S A, 103(49): 18499-503. [Abstract] [Full-text]
5. Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen.
   Vaccine, 25(2): 346-55. [Abstract] [Full-text]
6. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109.
   Vaccine, 25(3): 526-34. [Abstract] [Full-text]
7. Discontinued drugs in 2005: anti-infectives.
   Expert Opin Investig Drugs, 16(1): 1-10. [Abstract] [Full-text]
8. Synthesis and antigenic analysis of the BclA glycoprotein oligosaccharide from the Bacillus anthracis exosporium.
   Chemistry, 12(36): 9136-49. [Abstract] [Full-text]
9. Adenovirus-based Prime-boost Immunization for Rapid Vaccination Against Anthrax.
   Mol Ther, 15(1): 203-10. [Abstract] [Full-text]
10. The Design of Inhibitors for Medicinally Relevant Metalloproteins.
    ChemMedChem. [Abstract] [Full-text]
11. A fully integrated microfluidic genetic analysis system with sample-in-answer-out capability.
    Proc Natl Acad Sci U S A, 103(51): 19272-7. [Abstract] [Full-text]
12. Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis.
    Antimicrob Agents Chemother, 51(1): 215-22. [Abstract] [Full-text]
13. Inhibition of anthrax protective antigen outside and inside the cell.
    Antimicrob Agents Chemother, 51(1): 245-51. [Abstract] [Full-text]
14. Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule.
    Infect Immun, 75(1): 152-63. [Abstract] [Full-text]
15. Fully virulent Bacillus anthracis does not require the immunodominant protein BclA for pathogenesis.
    Infect Immun, 75(1): 508-11. [Abstract] [Full-text]
16. Chloroplast-derived anthrax and other vaccine antigens: their immunogenic and immunoprotective properties.
    Expert Rev Vaccines, 5(6): 839-49. [Abstract] [Full-text]
17. Specific electrochemical phage sensing for Bacillus cereus and Mycobacterium smegmatis.
    Bioelectrochemistry, 70(1): 180-4. [Abstract] [Full-text]
18. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
    Clin Cancer Res, 12(24): 7437-43. [Abstract] [Full-text]
19. Development of the Vaccine Analytic Unit's research agenda for investigating potential adverse events associated with anthrax vaccine adsorbed.
    Pharmacoepidemiol Drug Saf, 16(1): 46-54. [Abstract] [Full-text]
20. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
    J Infect Dis, 195(2): 174-84. [Abstract] [Full-text]
21. Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine.
    Proc Natl Acad Sci U S A, 103(52): 19707-12. [Abstract] [Full-text]
22. SILENCE: a new forward genetic technology.
    Nat Methods, 4(1): 51-3. [Abstract] [Full-text]

© 2005-2008 Anthrax Research Today. All Rights Reserved.